What is OncoResponse?
OncoResponse is a specialized biotechnology enterprise dedicated to the discovery and development of fully human monoclonal antibodies. The company operates at the intersection of immunology and oncology, utilizing a proprietary platform to identify therapeutic targets that address significant unmet medical needs. By focusing on patients who do not respond to existing immunotherapy treatments, OncoResponse aims to expand the reach of effective cancer care. Its market position is bolstered by a robust intellectual property portfolio and strategic partnerships with leading research institutions, allowing it to bridge the gap between academic discovery and commercial-grade therapeutic development.
How much funding has OncoResponse raised?
OncoResponse has raised a total of $203.2M across 10 funding rounds:
Private Equity
$29.5M
Series A
$9.5M
Series B
$40M
Debt
$150K
Debt
$416K
Series C
$40.6M
Debt
$50M
Other Financing Round
$14M
Grant
$13M
Other Financing Round
$6M
Private Equity (2015): $29.5M, investors not publicly disclosed
Series A (2015): $9.5M led by ARCH Venture Partners, Canaan Partners, and MD Anderson
Series B (2018): $40M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
Debt (2021): $416K backed by PPP
Series C (2021): $40.6M with participation from 3B Future Health Fund, Qatar Investment Authority, RiverVest Venture Partners, ARCH VENTURE PARTNERS, Canaan Partners, Redmile Group, BERING CAPITAL, Yonjin Venture, and Magnetar Group
Debt (2022): $50M led by Oxford Finance
Other Financing Round (2023): $14M supported by RiverVest Venture Partners, ARCH Venture Partners, and Canaan Partners
Grant (2023): $13M featuring Cancer Prevention and Research Institute of Texas
Other Financing Round (2025): $6M, investors not publicly disclosed
Key Investors in OncoResponse
ARCH Venture Partners
A leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often cofounding startups with scientists and entrepreneurs.
Canaan Partners
An early-stage venture capital firm that invests in technology and healthcare companies, backing founders from seed through growth stages in areas such as biopharma and digital health.
MD Anderson
One of the world's most respected centers focused on cancer patient care, research, education, and prevention, dedicated to ending cancer globally.
What's next for OncoResponse?
Looking ahead, the recent strategic investment will likely be deployed to accelerate the company's clinical pipeline and expand its research capabilities. As OncoResponse moves deeper into its development lifecycle, the focus will shift toward validating its lead candidates in human trials and potentially pursuing further collaborative agreements with larger pharmaceutical entities. The company's ability to maintain a steady cadence of financing, ranging from venture capital to strategic grants, suggests a disciplined approach to scaling its operations while maintaining its core mission of therapeutic innovation in the oncology space.
See full OncoResponse company page
